What to do when your insurance stops covering GLP-1 weight-loss medication
If your employer or state plan no longer covers Wegovy, Zepbound or another GLP-1 medicine for weight loss, this guide lists plans that have reported changes, with their sources, and walks through the options people look at next.
It is general information, not medical advice. Your plan's own documents are the final word on your coverage.
Starting price, billed every 4 weeks
Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.
See if I qualify →A licensed provider decides whether a prescription is appropriate.
Plans that have reported changes
Each entry below was reported by the source linked on it, on the date shown where the source gives one, and was last checked in November 2026. Plans change their rules often, so confirm with your own plan. The list is a sample of reported changes, not every plan.
Employers
Starbucks
Company health plans stop covering GLP-1 medicines for weight loss for benefits-eligible employees. Coverage for other conditions may continue.
Effective: Oct 1, 2026
Source: Business Insider (reported Aug 7, 2026)
Cigna (its own employee plan)
Cigna confirmed to ABC News that its employee health plan stopped covering GLP-1 medicines for weight loss.
Effective: Jul 1, 2026
Source: ABC News (reported Aug 2026)
PepsiCo
Reported to have cut coverage for weight loss while keeping it for diabetes. The report gives no start date.
Effective: Not stated
Source: ABC News (reported Aug 2026)
State, county and school plans
Massachusetts Group Insurance Commission (state employees)
The commission voted 10 to 7 to end coverage for obesity. Exceptions are described for people with a weight-related condition that qualifies.
Effective: Jul 1, 2026
In its place: The state introduced the Vida Health program, which is built around coaching.
Source: WBUR (reported Feb 26, 2026) · Also see: Commonwealth update on the program
Idaho state employee plan
Coverage of weight-loss GLP-1 medicines ended. Diabetes coverage is not affected.
Effective: Nov 1, 2025
In its place: The notice describes other options for members; read it or ask the plan.
Source: Boise State University news (reported Sep 11, 2025)
North Carolina State Health Plan
Coverage of weight-loss GLP-1 medicines ended in 2024. WRAL reported that the expected state budget would not restore it.
Effective: Apr 1, 2024
Source: WRAL (reported May 27, 2026)
Rutherford County, Tennessee
Weight-loss GLP-1 medicines are removed from the formulary, the plan's list of covered drugs. Type 2 diabetes use is unaffected, with prior authorization.
Effective: Jan 1, 2027
In its place: The county points employees to discount programs and lifestyle coaching, including Omada.
Source: Rutherford County (county notice)
Kalamazoo County, Michigan
Commissioners voted to end coverage of GLP-1 medicines prescribed strictly for weight loss, reversing an August plan that would have kept coverage with a copay. Diabetes use stays covered.
Effective: Jan 1, 2027
Source: MLive (reported Oct 2, 2026)
Mayflower Municipal Health Group (Massachusetts)
Weight-loss GLP-1 medicines are not covered, including for current users. Type 2 diabetes use is covered with prior authorization.
Effective: Jul 1, 2026
In its place: The group says it is looking into a weight-management program.
Source: Mayflower Municipal Health Group (plan notice)
Howard County Public Schools (Maryland)
Coverage of GLP-1 medicines for weight management was discontinued, with no new approvals after Dec 1, 2025. Diabetes use is unaffected.
Effective: Mar 31, 2026
Source: Howard County Public Schools (district notice)
Universities
MIT
Stricter eligibility rules for coverage, plus a required program.
Effective: Jan 1, 2027
In its place: Members must take part in 9amHealth, a clinical program the plan lists at no cost.
Source: MIT Human Resources (plan notice)
Harvard University
Stricter eligibility rules and a new authorization step for coverage.
Effective: Jan 1, 2026
In its place: Members must take part in 9amHealth at no extra cost.
Source: Harvard Human Resources FAQ (plan notice)
University of New Mexico
GLP-1 medicines for weight loss were removed from the drug plan.
Effective: Jul 1, 2026
In its place: Some employees keep a reimbursement option under the plan's own rules; the plan notice has the details.
Source: UNM Human Resources (plan notice)
Ohio State University
The 2026 medical plan excludes GLP-1 and GIP medicines for any use other than type 2 diabetes.
Effective: 2026 plan year
Source: Ohio State plan document (plan document)
Medicaid
Medi-Cal (California)
GLP-1 medicines prescribed solely for weight loss are no longer covered for adults 21 and older; the notice keeps coverage paths for certain other medical conditions. It also describes state fair hearing rights and suggests talking to your doctor.
Effective: Jan 1, 2026
Source: Medi-Cal Rx (member notice)
MassHealth (Massachusetts)
No longer covers these medicines when they are used only for obesity or overweight.
Effective: Jul 3, 2026
Source: Boston.com (reported Jun 27, 2026)
Rhode Island Medicaid
No longer covers GLP-1 medicines prescribed solely for weight loss. Prior authorization remains available for other medically necessary uses.
Effective: Oct 1, 2026
Source: Rhode Island EOHHS notice (reported Aug 13, 2026)
Changes that are not cuts
Some reported changes adjust what a member pays or what a plan asks for first. They are listed here so that a copay change is not mistaken for a loss of coverage.
Delaware state employee plan
The copay for weight-management GLP-1 medicines goes up for members who are not on Medicare. The copay for the diabetes class does not change.
Effective: Jul 1, 2026
Source: Delaware Department of Human Resources (plan FAQ)
Wisconsin Group Insurance Board
Approved covering anti-obesity medicines with their own cost-sharing. The release describes this as adding coverage, not cutting it.
Effective: Jan 1, 2027
Source: Wisconsin ETF (board news release)
Federal employee plans (FEHB and PSHB)
Carriers must still cover at least one GLP-1 anti-obesity medicine, but they require documented intensive behavioral therapy first.
Effective: Jan 1, 2027
Source: FedSmith (reported Oct 5, 2026)
What people look at when coverage ends
Appeal, or ask for an exception
If your plan denies a medication, its denial letter says how to ask for the decision to be reviewed (an appeal) and by when. Prior authorization is a related step: the plan asks your prescriber for documentation before it will pay.
Several plans above say they still cover these medicines for type 2 diabetes, and some describe exceptions for people with a qualifying condition. A medical-necessity letter is a letter from your prescriber explaining why a medication is needed for you. Ask your plan whether it accepts one and what it must include.
Not every plan allows exceptions. A plan that has removed a medication from its benefits may refuse them, so ask before spending time on paperwork.
Check your plan's alternative program
Some plans that ended drug coverage added a program in its place. The plans above mention 9amHealth, Vida Health and Omada. Some of these are listed as no-cost to members.
These programs are not the same thing as drug coverage, and what they include varies. Ask what the program provides, whether it is required and whether it connects to a prescriber.
Manufacturer self-pay programs
The makers of Wegovy and Zepbound each run a program for buying their medicine without insurance: NovoCare for Wegovy (Novo Nordisk) and LillyDirect for Zepbound (Eli Lilly).
Their terms change, so read them on the manufacturer's own site. Leland does not run or set the terms of either program.
Compounded medication through a telehealth provider
Leland offers an online intake for compounded semaglutide and tirzepatide. A licensed provider reviews it and decides whether a prescription is appropriate.
Leland's starting prices are $129 for semaglutide and $219 for tirzepatide, billed every 4 weeks. See Leland pricing for the plans.
Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.
What to ask your doctor
Bring these to an appointment, or send them to your prescriber. A doctor who knows your history is the person to talk through any of the options above.
- Do I have a diagnosis, such as type 2 diabetes, that my plan still covers these medicines for?
- If my plan allows exceptions, would you support a prior authorization request or write a letter of medical necessity?
- What are my options for my current treatment if coverage ends, and what would a change involve?
- Is there a program through my plan that I could enroll in, and can you help with its paperwork?
- If I look at a manufacturer self-pay program or a compounded medication, how do they differ, including their FDA status?
- What follow-up would you want if I change or pause treatment?
Insurance and GLP-1 coverage questions
Each plan gives its own reasons, so the linked notice or article is the place to read them.
See what treatment through Leland would involve
Start the intake. A licensed provider reviews it and decides whether a prescription is appropriate.
This page is general information, not medical advice. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. A qualified clinician determines whether treatment is appropriate for you.